

Europe Non-Invasive Prenatal Testing (NIPT) Market By Product (Consumables, Instruments), By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Application (Trisomy, Microdeletion Syndrome, Others), By End User (Diagnostic Laboratories, Hospitals, Others), By Country, Competition, Forecast and Opportunities, 2020-2030F

<https://marketpublishers.com/r/EC9418B11546EN.html>

Date: April 2025

Pages: 133

Price: US\$ 4,000.00 (Single User License)

ID: EC9418B11546EN

Abstracts

Market Overview

The Europe Non-Invasive Prenatal Testing (NIPT) Market was valued at USD 868.11 Million in 2024 and is projected to reach USD 1914.06 Million by 2030, growing at a CAGR of 14.06% during the forecast period. The market is witnessing strong growth driven by heightened awareness of genetic disorders and the rising demand for safer prenatal screening options. With maternal age steadily increasing across Europe, the risk of chromosomal abnormalities is also rising, prompting more expectant mothers to choose non-invasive alternatives to traditional procedures like amniocentesis. NIPT offers accurate results through a simple blood test, eliminating the risk of miscarriage and improving patient compliance. Supportive government policies, expanded private healthcare access, and advancements in genomic technologies are facilitating market expansion. The use of AI for test interpretation and the trend toward personalized medicine are broadening the scope of NIPT, while multiplex assay development and partnerships between diagnostics companies and healthcare providers are streamlining service delivery and improving accessibility.

Key Market Drivers

Rising Maternal Age and Associated Risk of Chromosomal Abnormalities

The growing maternal age across Europe significantly drives demand in the Non-Invasive Prenatal Testing (NIPT) market. As more women delay childbirth due to career, financial, and lifestyle choices, the likelihood of chromosomal disorders like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13) increases. According to the Office for National Statistics (ONS), the average age of mothers in England and Wales rose to 30.9 years in 2023. This demographic trend directly correlates with greater use of NIPT, which is non-invasive, highly accurate, and free of the miscarriage risks posed by conventional methods such as amniocentesis or chorionic villus sampling (CVS). NIPT uses maternal blood samples to analyze cell-free fetal DNA, providing a safe and reliable alternative for prenatal screening. In the UK, the National Health Service (NHS) has integrated NIPT into standard prenatal care, improving accessibility. As the average maternal age continues to rise across Europe, demand for accurate, non-invasive screening methods like NIPT is expected to grow substantially, reinforcing its role in modern prenatal care.

Key Market Challenges

High Cost of NIPT

The elevated cost of non-invasive prenatal testing (NIPT) remains a key barrier to widespread adoption across Europe. Advanced technologies such as next-generation sequencing and the need for specialized lab infrastructure contribute to the high per-test expense. In many countries, public healthcare systems do not fully reimburse NIPT, placing the financial burden on patients. This results in limited access for individuals from lower and middle-income groups, restricting overall market penetration. Additionally, pricing inconsistencies and variable insurance coverage create further challenges for both patients and providers. The cost factor also affects healthcare professionals' willingness to recommend NIPT and poses budget constraints for broader inclusion in public prenatal screening programs. For diagnostic firms, high operational and production expenses constrain market entry and expansion opportunities. Addressing these financial challenges will require expanded insurance support, government funding, and cost-efficient technological advancements to ensure equitable access to NIPT across the region.

Key Market Trends

Integration of NIPT into Routine Prenatal Care

One of the most significant trends in the European NIPT market is its growing incorporation into routine prenatal care. Advancements in genomics and the shift toward personalized medicine are making NIPT a standard first-line screening method. The test's accuracy in identifying common chromosomal abnormalities—along with its safety and non-invasive nature—has led healthcare providers to recommend it earlier in pregnancy. National healthcare programs in countries like Belgium and the Netherlands now offer government-funded NIPT to all pregnant women, resulting in high adoption rates. For instance, second-line NIPT uptake in regions like Andalusia, Spain has reached over 93% for eligible cases. Integration into care protocols enhances patient awareness and enables informed decision-making during early antenatal visits. Additionally, user-friendly platforms and automated analysis tools are improving operational efficiency for clinicians. This mainstreaming of NIPT is paving the way for broader utilization and supporting the transition to comprehensive, individualized prenatal care across Europe.

Key Market Players

F. Hoffmann-La Roche Ltd.

Eurofins LifeCodexx GmbH

Yourgene Health plc

Centogene N.V.

QIAGEN N.V.

Eluthia GmbH

Life Genomics AB

TATAA Biocenter AB

Genoma SA

Synlab International GmbH

Report Scope:

In this report, the Europe Non-Invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Product:

Consumables

Instruments

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Test Type:

Materni 21

Harmony

Panaroma

Verifi

NIFTY

Others

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Application:

Trisomy

Microdeletion Syndrome

Others

Europe Non-Invasive Prenatal Testing (NIPT) Market, By End User:

Diagnostic Laboratories

Hospitals

Others

Europe Non-Invasive Prenatal Testing (NIPT) Market, By Country:

Germany

France

United Kingdom

Italy

Spain

Russia

Poland

Bulgaria

Finland

Portugal

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Europe Non-Invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Europe Non-Invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends

4. VOICE OF CUSTOMER

5. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Product (Consumables, Instruments)
 - 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
 - 5.2.3. By Application (Trisomy, Microdeletion Syndrome, Others)
 - 5.2.4. By End User (Diagnostic Laboratories, Hospitals, Others)

- 5.2.5. By Country
- 5.2.6. By Company (2024)
- 5.3. Market Map

6. GERMANY NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Product
 - 6.2.2. By Test Type
 - 6.2.3. By Application
 - 6.2.4. By End User

7. FRANCE NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Product
 - 7.2.2. By Test Type
 - 7.2.3. By Application
 - 7.2.4. By End User

8. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Product
 - 8.2.2. By Test Type
 - 8.2.3. By Application
 - 8.2.4. By End User

9. ITALY NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value

9.2. Market Share & Forecast

- 9.2.1. By Product
- 9.2.2. By Test Type
- 9.2.3. By Application
- 9.2.4. By End User

10. SPAIN NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

10.1. Market Size & Forecast

- 10.1.1. By Value

10.2. Market Share & Forecast

- 10.2.1. By Product
- 10.2.2. By Test Type
- 10.2.3. By Application
- 10.2.4. By End User

11. RUSSIA NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

11.1. Market Size & Forecast

- 11.1.1. By Value

11.2. Market Share & Forecast

- 11.2.1. By Product
- 11.2.2. By Test Type
- 11.2.3. By Application
- 11.2.4. By End User

12. POLAND NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

12.1. Market Size & Forecast

- 12.1.1. By Value

12.2. Market Share & Forecast

- 12.2.1. By Product
- 12.2.2. By Test Type
- 12.2.3. By Application
- 12.2.4. By End User

13. BULGARIA NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

13.1. Market Size & Forecast

- 13.1.1. By Value
- 13.2. Market Share & Forecast
 - 13.2.1. By Product
 - 13.2.2. By Test Type
 - 13.2.3. By Application
 - 13.2.4. By End User

14. FINLAND NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 14.1. Market Size & Forecast
 - 14.1.1. By Value
- 14.2. Market Share & Forecast
 - 14.2.1. By Product
 - 14.2.2. By Test Type
 - 14.2.3. By Application
 - 14.2.4. By End User

15. PORTUGAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OUTLOOK

- 15.1. Market Size & Forecast
 - 15.1.1. By Value
- 15.2. Market Share & Forecast
 - 15.2.1. By Product
 - 15.2.2. By Test Type
 - 15.2.3. By Application
 - 15.2.4. By End User

16. MARKET DYNAMICS

- 16.1. Drivers
- 16.2. Challenges

17. MARKET TRENDS & DEVELOPMENTS

- 17.1. Merger & Acquisition (If Any)
- 17.2. Product Launches (If Any)
- 17.3. Recent Developments

18. EUROPE NON-INVASIVE PRENATAL TESTING (NIPT) MARKET: SWOT

Europe Non-Invasive Prenatal Testing (NIPT) Market By Product (Consumables, Instruments), By Test Type (Matern...

ANALYSIS

19. PORTERS FIVE FORCES ANALYSIS

- 19.1. Competition in the Industry
- 19.2. Potential of New Entrants
- 19.3. Power of Suppliers
- 19.4. Power of Customers
- 19.5. Threat of Substitute Products

20. COMPETITIVE LANDSCAPE

- 20.1. F. Hoffmann-La Roche Ltd.
 - 20.1.1. Business Overview
 - 20.1.2. Company Snapshot
 - 20.1.3. Products & Services
 - 20.1.4. Financials (As Reported)
 - 20.1.5. Recent Developments
 - 20.1.6. Key Personnel Details
 - 20.1.7. SWOT Analysis
- 20.2. Eurofins LifeCodexx GmbH
- 20.3. Yourgene Health plc
- 20.4. Centogene N.V.
- 20.5. QIAGEN N.V.
- 20.6. Eluthia GmbH
- 20.7. Life Genomics AB
- 20.8. TATAA Biocenter AB
- 20.9. Genoma SA
- 20.10. Synlab International GmbH

21. STRATEGIC RECOMMENDATIONS

22. ABOUT US & DISCLAIMER

I would like to order

Product name: Europe Non-Invasive Prenatal Testing (NIPT) Market By Product (Consumables, Instruments), By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Application (Trisomy, Microdeletion Syndrome, Others), By End User (Diagnostic Laboratories, Hospitals, Others), By Country, Competition, Forecast and Opportunities, 2020-2030F

Product link: <https://marketpublishers.com/r/EC9418B11546EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EC9418B11546EN.html>